Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The case for academic detailing with nurse practitioners.

Journal of the American Association of Nurse Practitioners·2016
Same author

Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.

Australian family physician·2008
Same author

Adults with diabetes - pharmacological management of hypertension.

Australian family physician·2008
Same author

Lipid lowering therapy for adults with diabetes.

Australian family physician·2008

Related Experiment Videos

Beta blockers in systolic heart failure.

Leslie Jackowski1, Roshmeen Azam

  • 1Sansom Institute, University of South Australia.

Australian Family Physician
|March 18, 2008
PubMed
Summary

Heart failure is a prevalent condition, particularly in older Australians. Early recognition and management in primary care, including the use of beta blockers with ACE inhibitors and diuretics, can reduce patient morbidity and mortality.

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • General Practice

Background:

  • Heart failure is a significant health concern in Australia, affecting 4% of individuals aged 45 and over.
  • Prevalence increases markedly with age, exceeding 50% in those 84 years and older.
  • Primary care increasingly manages heart failure patients, supported by national initiatives for early diagnosis.

Purpose of the Study:

  • To highlight the growing role of primary care in heart failure management.
  • To emphasize the importance of early recognition and diagnosis of heart failure.
  • To underscore the benefits of specific pharmacotherapies in heart failure treatment.

Main Methods:

  • This study is a review of current literature and clinical guidelines regarding heart failure management in primary care.

Related Experiment Videos

  • Analysis of epidemiological data on heart failure prevalence in Australia.
  • Review of evidence supporting the use of beta blockers, ACE inhibitors, and diuretics.

    • Main Results:

    • Heart failure management is shifting towards primary care settings.
    • National programs promote early detection and diagnosis.
    • Beta blockers, in conjunction with ACE inhibitors and diuretics, are proven to reduce morbidity and mortality.

    Conclusions:

    • Effective heart failure management is achievable in primary care.
    • Early diagnosis and intervention are crucial for improving patient outcomes.
    • Combination therapy with beta blockers, ACE inhibitors, and diuretics is a cornerstone of heart failure treatment.